HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status

Cancer Cytopathology

Volumn 123, Issue 12, 2015, Pages 745-754

  Richardson, Lyndsay Ann ^a   El Zein, Mariam ^a   Ramanakumar, Agnihotram V ^a   Ratnam, Samuel ^b,c   Sangwa Lugoma, Ghislain ^d   Longatto Filho, Adhemar ^e,f,g,h   Cardoso, Marly Augusto ^e   Coutlée, Francois ⁱ   Franco, Eduardo L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c Newfoundland and Labrador Public Health Laboratory   (Canada)

^d UNIVERSITY OF KINSHASA   (Congo)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF MINHO   (Portugal)

^g UNIVERSITY OF MINHO   (Portugal)

^h BARRETOS CANCER HOSPITAL   (Brazil)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

cervical cancer; human papillomavirus (HPV); Papanicolaou test; screening

Indexed keywords

VIRUS DNA;

ARTICLE; AWARENESS; BRAZIL; CANADA; CANCER SCREENING; COLPOSCOPY; CONGO; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA DETERMINATION; FALSE POSITIVE RESULT; HUMAN; INTERMETHOD COMPARISON; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; WART VIRUS; EARLY CANCER DIAGNOSIS; FEMALE; PAPILLOMAVIRUS INFECTION; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84962227763     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21596     Document Type: Article

References (36)

1. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F,. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res. 2009; 40: 478-485.
2. Mayrand MH, Duarte-Franco E, Rodrigues I, et al., Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357: 1579-1588.
3. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al., Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ. 2010; 340: c1804.
4. Ronco G, Giorgi-Rossi P, Carozzi F, et al., Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008; 100: 492-501.
5. Cuzick J, Arbyn M, Sankaranarayanan R, et al., Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008; 26 (suppl 10): K29-K41.
6. Naucler P, Ryd W, Tornberg S, et al., Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009; 101: 88-99.
7. Kitchener HC, Almonte M, Gilham C, et al,; ARTISTIC Trial Study Group. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009; 13: 1-150, iii-iv.
8. Agorastos T, Sotiriadis A, Emmanouilides CJ,. Effect of type-specific human papillomavirus incidence on screening performance and cost. Int J Gynecol Cancer. 2010; 20: 276-282.
9. Kulasingam SL, Rajan R, St Pierre Y, Atwood CV, Myers ER, Franco EL,. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Med. 2009; 7: 69.
10. Giorgi-Rossi P, Segnan N, Zappa M, et al., The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective. Int J Cancer. 2007; 121: 2729-2734.
11. Bergeron C, Giorgi-Rossi P, Cas F, et al., Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst. 2015; 107: dju423.
12. Benoy IH, Vanden Broeck D, Ruymbeke MJ, et al., Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. Am J Obstet Gynecol. 2011; 205: 569.e1-7.
13. Mayrand MH, Duarte-Franco E, Coutlee F, et al,; CCCaST Study Group. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer. 2006; 119: 615-623.
14. Sangwa-Lugoma G, Mahmud S, Nasr SH, et al., Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer. 2006; 119: 1389-1395.
15. Sangwa-Lugoma G, Ramanakumar AV, Mahmud S, et al., Prevalence and determinants of high-risk human papillomavirus infection in women from a sub-Saharan African community. Sex Transm Dis. 2011; 38: 308-315.
16. Tomita LY, Longatto Filho A, Costa MC, et al,; Brazilian Investigation into Nutrition and Cervical Cancer Prevention (BRINCA) Study Team. Diet and serum micronutrients in relation to cervical neoplasia and cancer among low-income Brazilian women. Int J Cancer. 2010; 126: 703-714.
17. Tomita LY, Roteli-Martins CM, Villa LL, Franco EL, Cardoso MA,. Associations of dietary dark-green and deep-yellow vegetables and fruits with cervical intraepithelial neoplasia: modification by smoking. Br J Nutr. 2011; 105: 928-937.
18. Tomita LY, D'Almeida V, Villa LL, Franco EL, Cardoso MA,; BRINCA Study Group. Polymorphisms in genes involved in folate metabolism modify the association of dietary and circulating folate and vitamin B-6 with cervical neoplasia. J Nutr. 2013; 143: 2007-2014.
19. Solomon D, Davey D, Kurman R, et al,; Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002; 287: 2114-2119.
20. Byrt T, Bishop J, Carlin JB,. Bias, prevalence and kappa. J Clin Epidemiol. 1993; 46: 423-429.
21. De Groot JA, Janssen KJ, Zwinderman AH, Bossuyt PM, Reitsma JB, Moons KG,. Correcting for partial verification bias: a comparison of methods. Ann Epidemiol. 2011; 21: 139-148.
22. Begg CB, Greenes RA,. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics. 1983; 39: 207-215.
23. Zhou X,. Comparing accuracies of two screening tests in a two phase study for dementia. Appl Stat. 1998; 47: 135-147.
24. Franco EL,. Statistical issues in human papillomavirus testing and screening. Clin Lab Med. 2000; 20: 345-367.
25. Choi BC,. Sensitivity and specificity of a single diagnostic test in the presence of work-up bias. J Clin Epidemiol. 1992; 45: 581-586.
26. Reichenheim ME, de Leon AP,. Estimation of sensitivity and specificity arising from validity studies with incomplete designs. Stata J. 2002; 2: 267-279.
27. Ringham BM, Alonzo TA, Grunwald GK, Glueck DH,. Estimates of sensitivity and specificity can be biased when reporting the results of the second test in a screening trial conducted in series. BMC Med Res Methodol. 2010; 10: 3.
28. Nanda K, McCrory DC, Myers ER, et al., Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000; 132: 810-819.
29. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M,. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer. 2005; 93: 862-867.
30. Ogilvie GS, van Niekerk DJ, Krajden M, et al., A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer. 2010; 10: 111.
31. Ogilvie GS, Krajden M, van Niekerk DJ, et al., Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-the HPV FOCAL Study. Br J Cancer. 2012; 107: 1917-1924.
32. Franco EL, Cuzick J, Hildesheim A, de Sanjose S,. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006; 24 (suppl 3): S3/171-177.
33. Ronco G, Cuzick J, Pierotti P, et al., Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ. 2007; 335: 28.
34. Stoler MH, Schiffman M,; Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001; 285: 1500-1505.
35. Louvanto K, Chevarie-Davis M, Ramanakumar AV, Franco EL, Ferenczy A,. HPV testing with cytology triage for cervical cancer screening in routine practice. Am J Obstet Gynecol. 2014; 210: 474.e1-7.
36. Bergeron C, Ronco G, Reuschenbach M, et al., The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments. Int J Cancer. 2015; 136: 2741-2751.